{
  "docId": "019de077-0f5f-77ef-a5cf-60b15fd5a5a5",
  "docSlug": "f1a62332dbdfff6b54feb25498e49e7e",
  "documentTitle": "Matinas BioPharma | Investor Presentation Deck | 29 slides",
  "authorId": "matinas-biopharma",
  "authorName": "Matinas BioPharma",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 29,
  "prevPage": 28,
  "nextPage": null,
  "slideType": "thesis_headline",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 1,
  "notes": "The slide combines a financial summary with a timeline of milestones and a strategic outlook.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0f5f-77ef-a5cf-60b15fd5a5a5/29",
  "deckHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5",
  "deckJsonHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5.json",
  "deckAnchorHref": "/decks/019de077-0f5f-77ef-a5cf-60b15fd5a5a5#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.2,
        "w": 0.2,
        "x": 0.365,
        "y": 0.58
      },
      "kind": "framework",
      "text": "Solid Value “Foundation”\nMAT2203 (Infection)\nClinically Validated\nClear Registration Pathway\nHighest unmet need",
      "attrs": null,
      "subkind": "instance",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8952e24e-4a0b-43bb-8cfd-55ae7ac05a92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.2,
        "x": 0.13,
        "y": 0.38
      },
      "kind": "list",
      "text": "Runway through Q3 2024\n$13.8M in Cash, Cash Equivalents and Marketable Securities\nNon-Dilutive Financing Options",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d75d031d-f589-4912-a6e0-991a01266fce",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.58,
        "x": 0.365,
        "y": 0.145
      },
      "kind": "list",
      "text": "Q1 - Successful Agreement with FDA for a Single Phase 3 Registration Trial to Support an NDA for MAT2203 for the Treatment of Invasive Aspergillosis (the “ORALTO” Trial)\nQ1 - LNC-docetaxel Maximum Tolerated Dose Longer Term Safety Study vs. IV-docetaxel\nQ2 - Potential MAT2203 Domestic/Regional/Global Partnership\nQ2 - Additional in vivo Oral Delivery of Small Oligonucleotides Targeting Inflammation\nQ2 - In vivo Evaluation of Additional Chemo-toxic Agents Delivered with LNCs\nQ2 - Evaluation of LNC-docetaxel in Additional Tumor Models\nQ4 - Commencement and First Patient Enrolled in ORALTO Phase 3 Trial",
      "attrs": null,
      "subkind": "timeline-item",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "646eae61-e3ee-4d9a-8f3e-71f69544a4b9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.25,
        "x": 0.69,
        "y": 0.55
      },
      "kind": "paragraph",
      "text": "Substantial UPSIDE\nLNC ORAL Delivery of Small Oligonucleotides in Inflammation\nLNCs to Improve Therapeutic Index of Chemotherapeutic Agents in Oncology\nToward\nEstablishing Internal and External Pipelines",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0f07fd69-912a-4b24-b459-58107109d3f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.06,
        "w": 0.24,
        "x": 0.105,
        "y": 0.09
      },
      "kind": "title",
      "text": "Investment Thesis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "35192331-1c52-4069-8956-9291fca14e0f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.58,
        "x": 0.365,
        "y": 0.055
      },
      "kind": "title",
      "text": "Near-Term Milestones – Setup for Strong Start to 2024",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e00cdfb-a6f4-42fb-a339-03ca452d9414",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Before-After-Bridge",
      "slug": "before-after-bridge",
      "agent": "Storyteller",
      "layer": "slide",
      "matchId": "1e340264-cea0-4ced-a6b6-fdf426e7bbbc",
      "evidence": "The slide mentions 'Setup for Strong Start to 2024', implying a before-after structure.",
      "confidence": 0.5
    },
    {
      "name": "Thesis archetype",
      "slug": "thesis-archetype",
      "agent": null,
      "layer": "slide",
      "matchId": "e55f716c-3a3b-48d5-b2dc-fe5e122ed20d",
      "evidence": "The slide presents a clear investment thesis with 'Near-Term Milestones – Setup for Strong Start to 2024' and 'Substantial UPSIDE'.",
      "confidence": 0.8
    }
  ],
  "frameworks": [
    {
      "name": "list-presentation",
      "slug": null,
      "matchId": "e839b60f-0a9d-450c-8fba-31abc7b2f092",
      "evidence": "Structured bullet points for value proposition",
      "confidence": 0.8
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 29,
      "from": 15,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "c020a8cd-19c2-4f66-b8fd-1a6de00826c3",
      "evidence": "The regulatory and development strategy for MAT2203 and the LNC platform are presented",
      "position": 2,
      "objective": "What are the near-term milestones and potential for growth?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}